Novo Integrated Sciences (NVOS) AI Stock Analysis

• Market Cap: $65.11K
• Dividend Yield: N/A
• Average Volume (3M): 48.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 19.62
• Revenue Growth: 5.75%
• EPS Growth: 55.68%
• Country: US
• Employees: 115
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 19,730,247
• 10 Day Avg. Volume: 15,803
• 30 Day Avg. Volume: 48,261
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.01
• Enterprise Value/Market Cap: 60.37
• Enterprise Value/Revenue: 0.07
• Enterprise Value/Gross Profit: 0.77
• Enterprise Value/Ebitda: -0.11
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: $0.00 ▼(-100.00%Downside)

The overall stock score for Novo Integrated Sciences is predominantly driven by the company's poor financial performance, characterized by negative profit margins and cash flow challenges. The lack of technical indicators prevents a deeper analysis of market trends, resulting in a neutral technical score. Valuation concerns due to negative earnings further underscore the financial instability. Without positive financial metrics or supporting technical data, the stock is rated at the lowest score.

Novo Integrated Sciences Business Overview & Revenue Model

Company Description

Novo Integrated Sciences, Inc. is a health and wellness company focused on providing comprehensive services and products that emphasize holistic health. The company operates in sectors such as healthcare services, technology, and regenerative medicine, offering a range of products and services designed to promote overall well-being. Novo Integrated Sciences is committed to integrating technology and science to deliver innovative solutions aimed at improving patient care and health outcomes.

How the Company Makes Money

Novo Integrated Sciences makes money through a diversified revenue model that includes healthcare services, product sales, and technology solutions. The company's key revenue streams are derived from its clinics and healthcare facilities, which offer a variety of services such as physiotherapy, chiropractic care, and other health-related services. Additionally, Novo Integrated Sciences generates income through the sale of health and wellness products, along with licensing and partnerships related to its proprietary technology and regenerative medicine solutions. Collaborations with healthcare providers and institutions further bolster its earnings by expanding its reach and service offerings.

Novo Integrated Sciences Financial Statement Overview

Summary

Novo Integrated Sciences is experiencing revenue growth, but profitability and cash flow challenges persist. The company struggles with negative margins and cash flows, indicating potential operational inefficiencies and financial sustainability issues. While leverage is controlled, declining equity ratios and negative ROE highlight financial instability. Strategic improvements in cost management and operational efficiency are crucial for future financial health.

Income Statement

Novo Integrated Sciences has shown consistent revenue growth over the years, with revenue increasing from $7.86M in 2020 to $13.29M in 2024. However, the company faces challenges with negative EBIT and net income, resulting in negative profit margins. In 2024, the EBIT margin was -75.8% and the net profit margin was -121.3%, indicating significant operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's debt-to-equity ratio improved slightly from 0.18 in 2020 to 0.32 in 2024, but remains relatively low, indicating conservative leverage. However, the equity ratio has decreased from 83.7% in 2020 to 46.3% in 2024, reflecting a declining proportion of equity in the asset structure. Return on equity is negative, primarily due to negative net income, which is a concern for profitability.

Cash Flow

Free cash flow has been consistently negative, with a significant decline in free cash flow growth from 2020 to 2024. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient operational cash flow to cover its losses. This raises concerns about the sustainability of operations without additional financing.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	13.29M	12.57M	11.74M	9.31M	7.86M
Gross Profit	5.74M	4.95M	4.80M	3.82M	3.06M
EBITDA	-10.08M	-5.85M	-22.48M	-2.58M	-2.78M
Net Income	-16.13M	-13.21M	-32.85M	-4.46M	-4.92M
Balance Sheet
Total Assets	32.14M	35.56M	40.87M	61.96M	35.39M
Cash, Cash Equivalents and Short-Term Investments	844.58K	416.32K	2.18M	8.29M	2.07M
Total Debt	4.71M	4.47M	13.00M	13.71M	4.39M
Total Liabilities	17.53M	11.06M	18.83M	18.15M	5.82M
Stockholders Equity	14.89M	24.82M	22.31M	43.86M	29.62M
Cash Flow
Free Cash Flow	-2.29M	-2.29M	-6.07M	-1.28M	-453.80K
Operating Cash Flow	-2.24M	-2.24M	-5.88M	-1.02M	-441.69K
Investing Cash Flow	-49.22K	-49.22K	163.46K	3.00M	657.13K
Financing Cash Flow	763.86K	763.86K	-427.12K	4.32M	-271.69K

Novo Integrated Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMS	69 Neutral	$16.32M	11.99	6.16%	―	35.25%	175.21%
Sector *	52 Neutral	$7.37B	-0.04	-63.81%	2.59%	16.40%	<0.01%
SYRA	50 Neutral	$1.43M	―	-94.29%	―	33.04%	39.30%
MODV	49 Neutral	$43.06M	―	-951.52%	―	-0.70%	-2.38%
CCEL	45 Neutral	$38.85M	380.00	93.38%	8.52%	1.10%	98.13%
CCM	41 Neutral	$23.45M	―	14.03%	―	-29.82%	-2.57%
NVOS	37 Underperform	$65.11K	―	-81.43%	―	5.75%	55.68%

Novo Integrated Sciences Corporate Events

Novo Integrated Sciences CEO Transition by May 31, 2025

On April 30, 2025, Novo Integrated Sciences announced that Robert Mattacchione’s resignation as CEO, initially set for February 5, 2025, has been extended multiple times to allow for a smooth transition, with the latest effective date no later than May 31, 2025. Despite stepping down as CEO, Mr. Mattacchione will continue as Chairman of the Board and Chairman of Novo Healthnet Limited. Additionally, Michael Pope resigned from the Board effective May 1, 2025, with both resignations not due to any disagreements with the company.